GlobeNewsWire
15 Jul 2026, 12:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
NeuroThera Labs has initiated a Phase IIb clinical trial site at Hannover Medical School for its Tourette Syndrome treatment candidate, SCI-110. — Advancing to Phase IIb is a critical milestone for a clinical-stage biotech, though it represents a mid-stage trial rather than a final result.
+0.40Prior Phase IIa results for SCI-110 demonstrated an average tic reduction of 21% among participants. — Positive efficacy data from previous phases reduces the risk profile for the current study and supports the asset's valuation.
+0.30The Phase IIb study will be conducted across multiple global sites, including Yale Child Study Center and Tel Aviv Sourasky Medical Center. — Diversifying trial sites increases the robustness of the data and the speed of patient enrollment.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company has advanced its proprietary treatment candidate SCI-110 to a Phase IIb clinical trial site in Germany.
The company's subsidiary has initiated a Phase IIb clinical trial for a Tourette Syndrome treatment following positive Phase IIa results.
Mentioned only as a marketplace where a subsidiary sells products, with no impact on Amazon's business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
28m ago
